LOTUSEYE
Lotus Eye Hospital and Institute financials
- Market cap
- ₹233 Cr
- Sector
- Healthcare
What Lotus Eye Hospital and Institute Limited does
Lotus Eye Hospital and Institute Limited runs a network of super-specialty ophthalmology hospitals across Tamil Nadu and Kerala, providing surgical and non-surgical eye-care services such as refractive surgery (LASIK/SMILE), cataract surgery, corneal and retinal treatment, glaucoma surgery and ocuplasty. It earns revenue from patient treatment and surgical procedures delivered at its hospital centers. The company also runs an affiliated optometry training institute (Lotus Bausch & Lomb Institute of Optometry) and conducts free community eye-care camps and screening drives.
Segments
- Refractive surgery
- Cataract surgery
- Cornea treatment
- Retina treatment
- Glaucoma treatment
- Ocuplasty
- Eye care centers
- 9 (7 in Tamil Nadu, 2 in Kerala)
- Cities covered
- Coimbatore, Salem, Tirupur, Mettupalayam, Karur, Kochi, Mulanthuruthy
- Cumulative surgeries performed
- 2 Lakh+
- Cumulative procedures performed
- 10 Lakh+
- Cumulative eyes screened
- 1 Crore+
- Qualified staff
- 300+
Quarterly results
Q1 FY27: revenue up 26.2%, net profit up 13.0% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 13 | 12 | 12 | 14 | 13 +1% | 14 +11% | 14 +18% | 17 +26% |
| EBITDA | 1 | 1 | -0 | 1 | 1 −33% | 1 −16% | 0 +382% | 3 +99% |
| Net profit | 0 | -0 | 0 | 1 | 0 +20% | -0 −8% | -0 −228% | 1 +13% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Performance −6.2% 1Y
1Y: ₹121.39 on 10 Sept 2025 → ₹113.9. High ₹141.38 (29 Jan 2026), low ₹98.22 (30 Mar 2026).
Financials, as filed
Revenue grew 5.6% a year over 2 years, FY24 to FY26. Operating margin narrowed to 6.3%.
| Year ending | FY24 | FY25 | FY26 |
|---|---|---|---|
| Revenue | ₹48 Cr | ₹50 Cr | ₹54 Cr |
| Operating profit | ₹7 Cr | ₹3 Cr | ₹3 Cr |
| Operating margin | 13.6% | 6.9% | 6.3% |
| Interest | ₹0 Cr | ₹0 Cr | ₹1 Cr |
| Depreciation | ₹4 Cr | ₹3 Cr | ₹4 Cr |
| Net profit | ₹3 Cr | ₹1 Cr | ₹0 Cr |
| Net margin | 6.0% | 1.5% | 0.1% |
| Cash from operations | ₹6 Cr | ₹3 Cr | ₹3 Cr |
| Free cash flow | ₹0 Cr | ₹-2 Cr | ₹-10 Cr |
| ROCE | 7.1% | 3.0% | 1.4% |
How to read this
From the company's own filings. Margins are computed from the filed sums; a year with an incomplete quarter is left blank rather than estimated.
Balance sheet
| Year ending | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| Equity capital | ₹21 Cr | ₹21 Cr | ₹21 Cr | ₹21 Cr | ₹21 Cr | ₹21 Cr |
| Reserves | ₹32 Cr | ₹34 Cr | ₹37 Cr | ₹39 Cr | ₹40 Cr | ₹39 Cr |
| Borrowings | ₹0 Cr | ₹1 Cr | ₹1 Cr | ₹1 Cr | ₹5 Cr | ₹16 Cr |
| Other liabilities | ₹6 Cr | ₹6 Cr | ₹5 Cr | ₹6 Cr | ₹6 Cr | ₹7 Cr |
| Total liabilities | ₹59 Cr | ₹62 Cr | ₹63 Cr | ₹67 Cr | ₹72 Cr | ₹83 Cr |
| Fixed assets | ₹41 Cr | ₹44 Cr | ₹44 Cr | ₹49 Cr | ₹55 Cr | ₹66 Cr |
| Capital work in progress | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr |
| Investments | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr |
| Other assets | ₹19 Cr | ₹18 Cr | ₹19 Cr | ₹18 Cr | ₹16 Cr | ₹17 Cr |
| Total assets | ₹59 Cr | ₹62 Cr | ₹63 Cr | ₹67 Cr | ₹72 Cr | ₹83 Cr |
How to read this
As filed each year. A line the company does not report — deposits for a non-lender, for instance — is left out rather than shown as a row of dashes.
Who owns it
As disclosed at Jun 2026
Since Jun 2025, the public added +0.28 pp while promoters trimmed −0.25 pp. The shareholder count shrank 13% to 9,627.
- Promoters
- 40.1%
- DIIs
- 0.0%
- Public
- 59.9%
Since Jun 2025
- Public +0.28 pp
- Promoters −0.25 pp
- FIIs −0.01 pp
How it drifted, 12 quarters
Over this window promoters fell from 57.6% to 40.1% — −17.4 pp.
Ownership split by quarter, oldest first. Sep '23: Promoters 57.6%, Public 42.4%.Dec '23: Promoters 56.6%, Public 43.4%.Mar '24: Promoters 41.4%, Public 58.6%.Jun '24: Promoters 40.2%, Public 59.8%.Sep '24: Promoters 40.0%, Public 60.0%.Dec '24: Promoters 40.1%, DIIs 0.0%, Public 59.8%.Mar '25: Promoters 40.2%, DIIs 0.0%, Public 59.7%.Jun '25: Promoters 40.4%, FIIs 0.0%, DIIs 0.0%, Public 59.6%.Sep '25: Promoters 40.6%, DIIs 0.0%, Public 59.3%.Dec '25: Promoters 40.7%, FIIs 0.0%, DIIs 0.0%, Public 59.3%.Mar '26: Promoters 40.1%, DIIs 0.0%, Public 59.9%.Jun '26: Promoters 40.1%, DIIs 0.0%, Public 59.9%.
Who bought this quarter
since Mar 2026
Disclosed holders that added to a position or appeared on the register for the first time, biggest addition first.
- Thomas Santosh +0.39 pp 2.66% held
- Kovai Purani Finance Private Limited +0.27 pp 7.93% held
- Urvija Choudhary +0.10 pp 1.42% held
- Asean Optics Private Limited newly disclosed 0.00% held
- Dr S K S Memorial Eye Hospitals Private Limited newly disclosed 0.00% held
- Eyeda Meds Llp newly disclosed 0.00% held
The same filing shows 0 holders trimming and 0 off the list — both are in the register beside this.
Who is on the register
Named in the Jun 2026 filing
Every holder of Lotus Eye Hospital and Institute Limited above SEBI's 1% disclosure line, and what changed since Mar 2026.
| Holder | Stake | Change |
|---|---|---|
| Sangeetha S . | 34.98% | unchanged |
| Kovai Purani Finance Private Limited | 7.93% | +0.27 pp |
| Vramath Investment Consultancy Private Limited | 4.84% | unchanged |
| Vramath Financial Services Private Limited | 4.67% | unchanged |
| Rajiv Choudhary | 4.53% | unchanged |
| Sangeeta Choudhary | 3.92% | unchanged |
| Kavetha Sundaramoorthy . | 2.75% | unchanged |
| Thomas Santosh | 2.66% | +0.39 pp |
| Late Kaliannagounder Sundaramoorthy | 2.41% | unchanged |
| Mahendran Devika | 1.97% | unchanged |
| K S Ramalingam | 1.46% | unchanged |
| Urvija Choudhary | 1.42% | +0.10 pp |
A holder disappearing from this list has fallen below the 1% line — it is not necessarily a sale. Percentages are of total shares, as disclosed in the company's own filing. Who was buying across the market this quarter.
Learn to analyse Lotus Eye Hospital and Institute Limited
Guides on how to read this kind of business and the numbers that matter.